SLC13A5-IN-1 是柠檬酸钠协同转运蛋白 (SLC13A5)选择性抑制剂，在 HepG2 细胞中阻断 14C-柠檬酸盐摄取的 IC50 : 0.022 μM。

SLC13A5-IN-1 is a selective inhibitor of sodium-citrate co-transporter (SLC13A5),completely blocks the uptake of 14C-citrate(IC50 : 0.022 μM in HepG2 cells).

In HepG2/14C-Citrate Uptake Assay,SLC13A5-IN-1 exhibits an IC50 of 0.022 μM . HepG2 cells endogenously express hSLC13A5 transporter which is responsible for the uptake of citrate into these cells. Uptake of 14C-citrate can be completely blocked by SLC13A5-IN-1 and the signal can be competed with unlabelled citrate.In recombinant hSLC3A5/14C-Citrate Uptake Assay, SLC13A5-IN-1 exhibits an IC50 of 0.056 μM . SLC13A5-IN-1 exhibits an IC50 of 100 μM in recombinant Human GlyT2/3H-Glycine Uptake Assay. The human embryonic kidney 293 cells are used that stably over-express the human GlyT2 receptor which is responsible for the uptake of glycine into these cells. Uptake of 3H-glycine can be completely blocked by SLC13A5-IN-1.

2227548-95-8

C19H19Cl3N2O3S

461.79

DMSO:5 mg/ml (10.83 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years